Drug intelligence / Profile preview

PTC-2116

Development stage: Unknown
Lead developer: Ponce Aurora
Modality: Peptides
Administration: Oral

Overview

PTC-2116 is a synthetic geropeptide developed by Ponce Therapeutics and its affiliate Ponce Aurora. It serves as the active component in the MitoX Blast (also known as MitoX Boost) energy beverage. Utilizing the MitoXcel technology platform, PTC-2116 is designed to target and stabilize the mitochondrial membrane potential (ΔΨm), thereby enhancing mitochondrial efficiency and cellular energy production in aging cells. Unlike traditional energy drinks that rely on caffeine, PTC-2116 aims to provide sustained exercise capacity and energy support without stimulatory side effects like jitters or crashes. It is positioned as a nutraceutical for general wellness and mitochondrial health rather than a pharmaceutical agent for specific disease treatment.

Brand names: MitoX BlastMitoX Boost
Other names: MitoXcel geropeptide

Beyond the preview

Go deeper on PTC-2116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTC-2116.

Explore the full profile